Chronic Spontaneous Urticaria and Bruton Tyrosine Kinase: A Multispecialty Expert Discussion - Episode 10

Early Clinical Trial Data for Rilzabrutinib in CSU and Future Study Directions

Published on: March 13, 2025

Giselle Mosnaim, MD, MS , Shyam Joshi, MD , Mark Lebwohl, MD, Jason Hawkes, MD, MS

Panelists discuss how rilzabrutinib shows promise in phase 2 trials with rapid improvements in disease activity scores (UAS7 and ISS7) starting from week 1 and a favorable safety profile, setting expectations for the upcoming phase 3 studies to confirm these initial findings.

EP. 1: Chronic Spontaneous Urticaria and Bruton Tyrosine Kinase: A Multispecialty Expert Discussion

EP. 2: Pathophysiology of Chronic Spontaneous Urticaria

EP. 3: Current CSU Treatment Approach and the Role of Bruton Tyrosine Kinase

EP. 4: BTK Inhibition as a Strategy for CSU Treatment

EP. 5: How BTK Inhibitors Differ From Current CSU Treatment Approaches

EP. 6: Overview of BTK Inhibitors in Development for CSU Treatment

EP. 7: Differentiating BTK Inhibition From Genetic BTK Deficiency

EP. 8: Overview of Remibrutinib Phase 3 Clinical Trials in CSU

EP. 9: CSU Burden of Disease and Quality of Life

Now Viewing

EP. 10: Early Clinical Trial Data for Rilzabrutinib in CSU and Future Study Directions

EP. 11: How BTK Inhibitors Might Address Unmet Treatment Needs in CSU

Video content above is prompted by the following:

Now let’s shift over to talk about rilzabrutinib, which is currently in phase 2 development. What are we seeing from the findings so far?
significant ISS7 changes seen as early as week 1
Rapid onset and favorable safety profile
Can you comment on what you’d like to see for rilzabrutinib as it enters phase 3 studies?